# Study of Lorlatinib in ROS1 Rearranged NSCLC

> **NCT03612154** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 35 (estimated)

## Conditions studied

- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT03612154
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-02
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03612154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03612154, "Study of Lorlatinib in ROS1 Rearranged NSCLC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03612154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*